A Florida woman filed a new product liability suit on June 9, 2026. A second mass recall — this one covering more than half a million pumps — landed just months earlier in February 2026. And California state courts just handed Medtronic a stinging appellate loss. The Medtronic MiniMed insulin pump lawsuit landscape has never been more active, or more consequential, for the roughly 800,000 diabetic patients across the country who have used one of these devices. This breaking-news recap covers every layer of the litigation, why no federal MDL has formed yet, and what injured patients must do before their legal clock runs out.
Two Major Recalls, One Dangerous Pattern
The Medtronic MiniMed insulin pump lawsuit story begins with a structural defect that the FDA ultimately classified as its most serious category of risk. In November 2019, Medtronic initiated a voluntary recall of its MiniMed 630G and 670G pumps after a retainer ring inside the device was found to crack or break under normal use. When the ring fails, the insulin cartridge can misalign — causing the pump to over-deliver or under-deliver insulin. Over-delivery triggers hypoglycemia, which can escalate to seizures, coma, or death. Under-delivery causes hyperglycemia and potentially fatal diabetic ketoacidosis (DKA). According to FDA medical device recall records, Medtronic had already received 26,421 complaints — including 2,175 injury reports and one confirmed death — before pulling the devices from use.
The FDA formally classified the retainer-ring recall as Class I in February 2020, meaning the agency determined there was a reasonable probability that use of the product would cause serious adverse health consequences or death. The original recall covered 322,005 pumps manufactured before October 2019 (630G) and August 2019 (670G). In October 2021, Medtronic expanded the recall proactively, replacing all 600-series pumps equipped with clear retainer rings with black-ring models — bringing the total number of affected devices to approximately 500,000 units.
Plaintiffs’ attorneys in the ongoing Medtronic MiniMed insulin pump lawsuit filings frequently cite Medtronic’s prior history with its older Paradigm pump line, which was the subject of multiple FDA recalls between 2009 and 2017 for blocked membranes, infusion set defects, and motor malfunctions. That pattern, they argue, is evidence of a systemic and long-standing quality-control failure — not an isolated engineering mistake.
The February 2026 Class II Recall: 562,659 More Pumps
Just as the original retainer-ring litigation was gaining momentum in state courts, the FDA announced a second significant recall in February 2026 — this time targeting Medtronic’s newer 700-series pumps. The recall covers 562,659 devices across three models: 13,811 MiniMed 700G pumps, 95,704 MiniMed 770G pumps, and 453,144 MiniMed 780G pumps. The defect is a fluid-pressure issue: when the pump is positioned more than 14 inches above the infusion site, back-pressure can cause a dangerous over-delivery of insulin. The FDA classified this as a Class II recall, indicating a risk of temporary or medically reversible adverse health consequences.
According to FDA safety recall announcements, Medtronic began notifying affected customers starting February 13, 2026, using a multi-channel outreach approach that included email, SMS, certified mail, and in-app notifications through the pump’s companion software. Patients were instructed to keep the pump below the 14-inch threshold relative to their infusion site — a behavioral workaround that critics argue places an unreasonable burden on diabetic patients who already manage an extraordinarily complex daily regimen. This second recall is expected to generate a new wave of Medtronic MiniMed insulin pump lawsuit filings through 2026 and into 2027.
| Recall Event | Models Affected | Units Affected | FDA Classification | Key Defect |
|---|---|---|---|---|
| Nov 2019 / Feb 2020 (original) | MiniMed 630G, 670G | 322,005 (expanded to ~500,000) | Class I | Retainer ring crack → insulin misdelivery |
| Feb 2026 (new recall) | MiniMed 700G, 770G, 780G | 562,659 | Class II | Fluid pressure → over-delivery when pump >14 in. above site |
June 9, 2026: Florida Lawsuit Puts MiniMed 780G Back in the Spotlight
Three weeks ago, on June 9, 2026, a Palm Beach County woman named Christine Hunter filed a product liability lawsuit in Palm Beach County Circuit Court, putting the newest model — the MiniMed 780G — directly in the litigation crosshairs. According to the complaint, Hunter’s pump stopped delivering insulin on June 12, 2022, causing her to lapse into a diabetic coma. The lawsuit alleges that Medtronic failed to adequately design, manufacture, and warn users about the risks associated with the 780G model.
Hunter’s case is particularly significant because it involves the same pump model at the center of the February 2026 Class II recall, and because it highlights a pattern that personal injury attorneys across the country are tracking closely: pump failures causing acute, life-threatening events in patients who had every reason to trust their device. If you or a family member suffered a serious injury linked to a defective insulin pump, understanding the potential value of your claim is a critical first step — a medical malpractice calculator can provide a preliminary estimate of damages based on the nature and severity of your injuries. The Hunter filing signals that new cases are being filed regularly and that the litigation is nowhere near its peak.
California Bellwether Cases Survive Medtronic’s Preemption Defense
Perhaps the most legally significant development in the broader Medtronic MiniMed insulin pump lawsuit landscape is what is happening in California state courts. Multiple cases pending in Los Angeles Superior Court have survived not only Medtronic’s motion for summary judgment, but also a formal appellate preemption challenge. The California Court of Appeal’s decision in Case No. B348034 — Medtronic MiniMed v. Superior Court of Los Angeles County — rejected Medtronic’s argument that federal preemption bars all state-law claims against the company.
Medtronic’s preemption defense is grounded in the U.S. Supreme Court’s 2008 ruling in Riegel v. Medtronic, which held that the Medical Device Amendments to the Food, Drug, and Cosmetic Act preempt state tort claims that impose requirements different from or additional to federal requirements for Class III devices that received Premarket Approval (PMA). Medtronic argues its MiniMed pumps, as PMA-approved devices, are shielded from state liability. Two federal judges agreed: in 2023, a judge in the Western District of Oklahoma dismissed Warmoth v. Medtronic with prejudice on preemption grounds. However, the Riegel framework does not preempt claims that are premised on violations of federal requirements themselves — and California courts have found plaintiffs’ parallel-claim theories survive that threshold. The appellate victory in Case No. B348034 has been described by legal observers as “another defeat for Medtronic’s efforts to avoid facing justice” and is being studied closely by plaintiffs’ attorneys filing in other state jurisdictions.
Why There Is No Federal MDL — And What That Means for You
One of the most common questions injured patients ask is: why hasn’t a federal Multidistrict Litigation (MDL) been formed for the Medtronic MiniMed insulin pump lawsuit? The short answer is volume and coordination. MDL formation under 28 U.S.C. § 1407 requires the Judicial Panel on Multidistrict Litigation to find that centralization will promote the convenience of parties and witnesses and will advance the efficient conduct of litigation. As of mid-2026, the MiniMed cases have not yet reached the volume or coordination threshold required for federal MDL designation. Individual suits remain filed in their originating state or federal courts, which means each plaintiff currently faces Medtronic’s powerful preemption defense independently.
This decentralized landscape cuts both ways. On the one hand, California plaintiffs have a proven appellate roadmap to defeat preemption. On the other hand, plaintiffs in federal courts — particularly in more conservative circuits — face a much steeper climb. Separately, a securities fraud lawsuit brought by Medtronic investors was dismissed twice and is now pending before the Eighth Circuit on appeal. And a cybersecurity class action filed in the Central District of California in August 2023 alleges that Medtronic’s InPen and MiniMed companion apps shared sensitive health data — including insulin dosing and glucose readings — with Google via Google Analytics without patient consent, potentially violating HIPAA. In the one bellwether wrongful death case out of Kentucky, Medtronic reached a settlement on undisclosed terms in October 2024. For families who have lost a loved one due to a pump malfunction, understanding the full range of damages available is essential — a wrongful death calculator can help surviving family members assess the economic and non-economic value of their potential claim.
What Injured Patients Must Do Right Now
Statutes of limitations in product liability cases vary by state but typically run two to three years from the date of injury discovery. Patients who were injured during the 2019–2022 recall period may be approaching — or may have already passed — their filing deadlines in some states. Patients injured in connection with the February 2026 Class II recall have more time, but waiting is still a critical mistake. If you used any MiniMed 600-series or 700-series pump and experienced a serious adverse event — including hypoglycemia, seizures, DKA, coma, or hospitalization — you should take the following steps immediately.
- Preserve your device: Do not return, destroy, or discard the pump. The physical device is crucial evidence.
- Request your medical records: Gather all records related to your hospitalization, emergency care, and ongoing diabetes management.
- Document the recall notice: If you received a correction notice from Medtronic in February 2026 or an earlier recall notice, save it in its original form.
- Report to the FDA: File a MedWatch adverse event report at the FDA’s official portal so your injury is part of the formal record.
- Calculate your general injury damages: Before meeting with a mass tort attorney, use a personal injury settlement calculator to get a baseline estimate of what your economic and non-economic damages may be worth.
- Consult a mass tort attorney immediately: The preemption landscape is complex and highly jurisdiction-dependent. Choosing the right court to file in — state versus federal — may be the single most important strategic decision in your case.
The Medtronic MiniMed insulin pump lawsuit litigation is one of the most consequential defective medical device cases of 2026. With two recalls totaling more than one million units, a fresh lawsuit filed just weeks ago, California appellate victories rewriting the preemption playbook, and statutes of limitations ticking for thousands of patients, the window to act is narrowing fast. Do not wait for a federal MDL to form — your individual case may need to be filed now to preserve your rights.
Frequently Asked Questions
Who is eligible to file a Medtronic MiniMed insulin pump lawsuit?
You may be eligible to file a Medtronic MiniMed insulin pump lawsuit if you used a MiniMed 630G, 670G, 700G, 770G, or 780G insulin pump and suffered a serious adverse event — including hypoglycemia, seizures, diabetic coma, DKA, or hospitalization — that you believe was caused by a pump malfunction. Family members of patients who died as a result of a pump defect may also have standing to bring a wrongful death claim. Because statutes of limitations vary by state, typically running two to three years from the date of injury discovery, you should consult a mass tort attorney as soon as possible to assess whether your claim is still timely.
What is the difference between the Class I and Class II MiniMed recalls?
The original Class I recall, initiated in November 2019 and formally classified by the FDA in February 2020, covered approximately 322,005 MiniMed 630G and 670G pumps with a defective retainer ring that could crack and cause catastrophic insulin misdelivery — a risk the FDA considered potentially life-threatening. The recall was later expanded to approximately 500,000 units. The February 2026 Class II recall covers 562,659 MiniMed 700G, 770G, and 780G pumps with a fluid-pressure defect that poses an over-delivery risk when the pump is held more than 14 inches above the infusion site. Class II indicates a lower but still significant risk of temporary or medically reversible harm. Both recalls support independent product liability claims.
Why did some federal courts dismiss MiniMed lawsuits while California courts allowed them to proceed?
The legal conflict stems from the U.S. Supreme Court’s 2008 decision in Riegel v. Medtronic, which generally preempts state tort claims against Class III medical devices that received FDA Premarket Approval (PMA). Some federal courts — including the Western District of Oklahoma in Warmoth v. Medtronic in 2023 — have agreed with Medtronic that PMA approval bars all state-law claims. California state courts, however, have found that plaintiffs can pursue “parallel claims” — claims that allege Medtronic violated its own federal obligations, not simply state standards that exceed federal requirements. The California Court of Appeal confirmed this approach in Case No. B348034 in an appellate ruling that rejected Medtronic’s preemption challenge. Choosing the right jurisdiction to file your case is therefore critically important.
Has Medtronic settled any MiniMed insulin pump lawsuits?
Yes, at least one case has settled. A wrongful death case brought in Kentucky reached a settlement with Medtronic in October 2024 on undisclosed terms. However, there is no global class-wide or MDL-wide settlement as of mid-2026. Because no federal Multidistrict Litigation has been formed, each case is being litigated — and settled — individually. The absence of a global settlement means injured patients and families must actively pursue their own claims rather than waiting for a mass resolution. The undisclosed nature of the Kentucky settlement terms underscores the importance of individual legal representation to negotiate the best possible outcome.
What is the statute of limitations for filing a MiniMed insulin pump lawsuit?
Statutes of limitations for product liability claims vary by state but most commonly range from two to three years from the date you discovered — or reasonably should have discovered — that your injury was linked to the pump. For patients injured during the 2019–2022 recall period, some state deadlines may be approaching or may have already passed. Patients who received the February 2026 Class II recall notice and subsequently identified an injury have more time, but delay remains risky. Certain states have separate statutes of repose that can extinguish claims regardless of when the injury was discovered. The only way to know your exact deadline is to consult a mass tort attorney in your state immediately.
Legal Disclaimer: This article is provided for informational purposes only and does not constitute legal advice, nor does it create an attorney-client relationship.
Related reading: Pressure Cooker Burn Injury Lawsuit: Verdict & Damages When Lids Fail Under Pressure
Related reading: Psychiatric Malpractice Settlement Amounts: 2026 Data, Verdicts & How Compensation Is Calculated
Victoria Chambers is a mass tort and class action research analyst with extensive knowledge of multi-district litigation (MDL), defective product cases, dangerous drug lawsuits, and toxic exposure claims across the United States. Victoria is not an attorney and the information provided is for educational purposes only.